CompletedPhase 2NCT03802617

A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Studying Uremic pruritus

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Kissei Pharmaceutical Co., Ltd.
Principal Investigator: Naomi Koshihara
Clinical Development Div.
Intervention: MR13A9(drug)
Enrollment: 247 target
Eligibility: 20 years · All sexes
Timeline: 2019 – 2019

Study locations (1)

Research Site, Multiple Locations, Japan

Collaborators

Maruishi Pharmaceutical

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03802617 on ClinicalTrials.gov

Other trials for Uremic pruritus

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06446310
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Qilu Pharmaceutical (Hainan) Co., Ltd.

See all trials for Uremic pruritus →

← Back to all trials